Treatment of AIDS-Related Kaposi Sarcoma When Paclitaxel or Docetaxel Has Failed
This protocol addresses AIDS-related Kaposi sarcoma that has not responded adequately to second-line chemotherapy. It defines the next therapeutic step when the prior treatment line failed to achieve its goals.
The preceding line employed paclitaxel or docetaxel as second-line systemic chemotherapy, given in combination with ongoing antiretroviral therapy. Escalation to this protocol is indicated when that regimen did not achieve regression of Kaposi sarcoma lesions — specifically when reduction in size, thickness, and coloration of tumors, and reduction of edema, were not attained.
Salvage systemic chemotherapy, maintained alongside ongoing antiretroviral therapy, forms the basis of management at this stage — the full regimen options are detailed in the structured protocol below.
References
DOI: 10.1111/ddg.14788
As a salvage treatment after anthracycline or paclitaxel therapy, oral etoposide, irinotecan, the previously used ABV regimen (adriamycin or doxorubicin with bleomycin and vincristine) as well as Gemcitabine may also be considered.
View source ↗